On February 26, 2021 Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, reported that management will be holding one-on-one meetings with investors during the Virtual 33rd Annual Roth Conference, being held March 15 – 17, 2021 (Press release, Celsion, FEB 26, 2021, View Source [SID1234575779]). A webcast of Celsion’s presentation will be pre-recorded and will be available on the Company’s website during the week before the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Institutional and other investors interested in meeting with Celsion during the conference should contact their Roth Capital Partners sales representative or LHA Investor Relations. Conference information is available at www.roth.com/oc2021virtual.